Press release
Global Thalassemia Market Will Reach At A Highest CAGR Of 10.29% By 2026|Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.
Global Thalassemia Market
This Thalassemia market report considers various factors that have direct or indirect effect on the development of business which includes historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the healthcare industry. Important industry trends, market size, and market share are analysed and discussed in detail in this Thalassemia market research report. By understanding the minds of target markets, attitudes, feelings, beliefs and value systems, this market research report has been prepared. The report makes you visualize what the healthcare
industry is doing which lends more credibility and trust.
Get Sample Copy Of This Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-thalassemia-market
Few of the major competitors currently working in the thalassemia market are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte Corporation; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza and Sangamo Therapeutics.
Key Developments in the Market:
In April 2019, CELGENE CORPORATION and Acceleron Pharma, Inc. announced that CELGENE had submitted a Biologics License Application (BLA) for "luspatercept" with the U.S. F.D.A. (United States Food & Drug Administration). This will help in faster commercialization and development of drugs for patients suffering from blood diseases.
In January 2019, Vifor Pharma announced positive results from their phase-I trial of "VIT-2763" an oral ferroportin inhibitor. The drug being developed for transportation of iron from one cell to another has shown signs in reduction of serum iron in a dose-dependent state.
COMPETITIVE ANALYSIS:
Global thalassemia market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of thalassemia market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
Inquiry For Customize Report With Discount at : https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-thalassemia-market
Segmentation: Global Thalassemia Market
By Thalassemia Type
Alpha Thalassemia
Beta Thalassemia
By Therapeutic Class
Iron Chelating Drugs
Exjade/Jadenu (deferasirox)
By Pipeline
Gene Therapy
LentiGlobin
By End-User
Hospitals
Clinics
Research Institutes
Laboratories
By Geography
North America
South America
Europe
Asia-Pacific
Middle East & Africa
Market Drivers
Increasing prevalence of the disease globally without any viable treatment options available for curing the disease; this factor is expected to drive the market growth
Growth in development of pipeline drugs and development of new therapies because of R&D activities and investments by the various authorities; this factor is expected to drive the market growth
Market Restraint
Lack of viable treatment options commercialized for the treatment of disease/disorder rather than the symptoms associated with the disease; this factor is expected to restrain the market growth
High cost of treatment for the disorder is expected to act as a restraint to the market growth
Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-thalassemia-market
Contact:
Data Bridge Market Research
Tel: +1-888-387-2818
Email: Corporatesales@databridgemarketresearch.com
About Data Bridge Market Research
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Thalassemia Market Will Reach At A Highest CAGR Of 10.29% By 2026|Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc. here
News-ID: 1944561 • Views: …
More Releases from Data Bridge Market Research
Telepsychiatry Market Size, Share, and Trends Analysis Report to Observe Promine …
Data Bridge Market Research analyses that the telepsychiatry market which was USD 6.02 billion in 2021, is expected to reach USD 15.45 billion by 2029, at a CAGR of 12.50% during the forecast period 2022 to 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth…
Synthetic and Bio-based Butadiene Market Size, Share, and Trends Analysis Report …
Data Bridge Market Research analyses that the synthetic and bio-based butadiene market will witness a CAGR of 9.00% for the forecast period of 2022-2029.
Market Definition:
Butadiene is a non-corrosive, colourless, highly reactive and aromatic gas that is used for the production of plastic and synthetic rubber. It is one of the most important industrial gases that can be condensed to liquid at a specific temperature. Butadiene can be produced from both…
Stretch Hood Films Market Size, Share, and Trends Analysis Report to Observe Pro …
Stretch Hood Films Market was valued at USD 759.88 million in 2021 and is expected to reach USD 1448.70 million by 2029, registering a CAGR of 8.40% during the forecast period of 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, import/export…
Sticker Labeling Machine Market to Observe Prominent CAGR in the 4.20% by 2029, …
Data Bridge Market Research analyses that the sticker labeling machine market was valued at USD 875.00 million in 2021 and is expected to reach USD 1216.05 million by 2029, registering a CAGR of 4.20% during the forecast period of 2022 to 2029.
Market Definition:
The sticker labelling machines work on the system by using lightweight delicate marks which are pressed on the products. All the sticker labelling machines do all the markings…
More Releases for Thalassemia
Thalassemia Market to Witness Growth Acceleration | SG Pharma Pvt. Lmt.
The Thalassemia Market Report is designed to incorporate both qualitative and quantitative aspects of the industry with respect to each region and country involved in the study. Furthermore, It studies the market essential sectors such as top participants, expansion strategies, business models, and other industry features to improve the current strategy of key players. Facts and data are presented in reports using diagrams, graphs, pie charts, and other pictorial representations.…
Global Thalassemia Market Size – Forecast to 2026
The findings reviewed by GME stated that the Global Thalassemia Market will expand with a CAGR value of 10.2 percent from 2021 to 2026. Several drivers are likely to accelerate the thalassemia market further, including an increasing occurrence of thalassemia, growing public awareness, expanding expenditure in research & development, and the growing need for improved curative gene therapy.
Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and…
Thalassemia Treatment Market is driven by increase in number of altered thalasse …
Thalassemia Treatment Market - Snapshot
The global thalassemia treatment market is driven by increase in number of altered thalassemia genes across the globe. The global market was valued at US$ 842.0 Mn in 2017 and is projected to expand at a CAGR of 7.9% from 2018 to 2026 to reach US$ 1,639.6 Mn by 2026. The global market is witnessing high growth owing to increase in blood transfusion and chelation therapy…
Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)
Market Research Hub (MRH) has recently broadcasted a new study to its broad research portfolio, which is titled as “Global Thalassemia Market: Industry Analysis & Outlook (2017-2021)” report studies Thalassemia is a blood disorder that causes abnormal production of hemoglobin in an affected person. It is a genetic disorder inherited from parents. Hemoglobin carries oxygen in the blood and is produced by two proteins called alpha globin and beta globin.…
Thalassemia - Pipeline Review, H2 2017
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H2 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow…
Thalassemia - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Thalassemia - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia - Pipeline Review, H1 2017, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.
Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms…
